Research progress on regulation of P-glycoprotein by reactive oxygen species

Chinese Pharmacological Bulletin

Volumn 26, Issue 10, 2010, Pages 1386-1390

  Dong, Xian Zhe ^a   Bi, Ming Gang ^b  

^a HARBIN UNIVERSITY OF COMMERCE   (China)

^b INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

Author keywords

Excitomotory; Multidrug resistance; P glycoprotein; Reactive oxygen species; Reversal; Tumor

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; REACTIVE OXYGEN METABOLITE;

ARTICLE; MEDICAL RESEARCH; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TUMOR CELL;

EID: 78651103045     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Martin L. Recent advances in the development of P-gp inhibitors [J]. Anticancer Agents Med Chem, 2009, 9(4): 415-36.
2. Wang Q, Strab R, Kardos P, et al. Application and limitation of inhibitors in drug-transporter interactions studies[J]. Int J Pharm, 2008, 356(1-2): 12-8.
3. Hirose M. The process behind the expression of mdr-1/P-gp and mrp/MRP in human leukemia/lymphoma[J]. Anticancer Res, 2009, 29(4): 1073-7.
4. Tu C H, Yang D Z. Molecular structure and functions of P-glycoprotein[J]. Chin J Biochem Mol Biol, 2009, 25(1): 7-11.
5. Zhang X P, Tao Y H, Chen Q L, et al. Establishm and characteristics of a paclitaxel resistant human mammary adenocarcinoma cell subline (MCF-7/Taxol)[J]. Chin Pharmacol Bull, 2008, 24(6): 804-9.
6. Liu Y, Cui D W. P-glycoprotein and cancer multidrug resistance [J]. Hainan Med J, 2010, 21(1): 117-9.
7. The human ATP-binding cassette (ABC) transporter supperfamily [J]. J Lipid Res, 2001, 21: 1007-17.
8. Zeng W, Lei Z M. The research progress of P-glycoprotein and P-glycoprotein inhibitor[J]. J Mil Surg Southw China, 2010, 12(1): 114-6.
9. Takeshita A, Shigeno K, Shinjo K, et al. All-trans retinoic acid (ATRA) differentiates acute promyelocytic leukemia cells independently of P-glycoprotein (P-gp) related multidrug resistance [J]. Leuk Lymphoma, 2001, 42(4): 739-46.
10. Li B. The structure-activity relationship of multidrug resistance reversal agents which is mediated by P-glycoprotein[J]. Fore Med Sci Sect Pharm, 2000, 27(5): 264-8.
11. Ralph S J, Rodríguez-Enríquez S, Neuzil J, et al. The causes of cancer revisited : "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy[J]. Mol Aspects Med, 2010, 31(2): 145-70.
12. Wartenberg M, Ling F C, Muschen M, et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor(HIF-1) and reactive oxygen species[J]. Faseb J, 2003, 17(3): 503-5.
13. 2+ overload[J]. Cell Sci, 2008, 121: 3133-9.
14. Charles P, Kim Caryn N, Guo F F, Bhalla Kapil N. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-XI[J]. Blood, 2000, 95: 1014-22.
15. Shuang L M, Cheng C A, Ye W, et al. Trichomislin, a novel ribosome-inactivating protein, induces apoptosis that involves mitochondria and caspase-3[J]. Archives Biochem Biophys, 2005, 434(2): 258-65.
16. Ziemann C, Burkle A, Kahl G F, Hirsch-Ernst K I. Reactive oxygen species participate in mdrlb mRNA and P-glycoprotein overexpression in primary rat hepatocyte cultures[J]. Carcinogenesis, 1999, 20(3): 407-14.
17. Anna M, Gunamani S, Anderson L M. Mutant K-rasV12 increases COX-2, peroxides and DNA damage in lung cells[J]. Carcinogenesis, 2004, 25(11): 2231-7.
18. Vimal AP, Michael J D, Sorokin A. Regulation of MDR-1 (P-glycoprotein) by Cyclooxygenase-2[J]. Biol Chem, 2002, 277(41): 38915-20.
19. Zatelli M C, Luchin A, Tagliati F, et al. Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression[J]. Endocr Relat Cancer, 2007, 14(4): 1029-38.
20. Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in cancer[J]. EMBO Rep, 2002, 3(5): 420-5.
21. Maria W, Ling F C, Maurice S, et al. Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroidsby reactive oxygen species[J]. Biol Chem, 2001, 276(20): 17420-8.
22. Xu Z, Yang J, Yu J, et al. Effects of BSO, GSH, Vit-C and DMPS on the nephrotoxicity of mercury[J]. Toxicol Ind Health, 2007, 23(7): 403-10.
23. Shan X Y, Chen B A, Xia G H, et al. Reversal of multidrug-resistance in human leukemia cell line K562/A02 by tyrosine kinase inhibitors[J]. J Exp Hematol, 2010, 18(1): 90-5.
24. Maria W, Madeleine R, Andre D, et al. Glycolytic pyruvate regulates P-glycoprotein expressionin multicellular tumor spheroids via modulation of the intracellular redox state[J]. Cell Biochem, 2010, 109: 434-46.
25. Maria W, Edda H, Heinrich S, et al. Reactive oxygen species-linked regulation of the multidrug resistance transporter P-glycoprotein in Nox-1 overexpressing prostate tumor spheroids[J]. FEBS Lett, 2005, 579: 4541-9.
26. Safrit J T, Berek J S., Bonavida B. Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype[J]. Gynecol Oncol, 1993, 48(2): 214-20.
27. Silvina E, Hava G, Virginie P, et al. H-ferritin subunit overexpression in erythroid cells reduces the oxidative stress response and induces multidrug resistance properties[J]. Blood, 1999, 94: 3593-603.
28. Ralph S J, Rodríguez-Enríquez S, Neuzil J, Moreno-Sánchez R. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger [J]. Mol Aspects Med, 2010, 31(1): 29-59.
29. Liu C L, Wang H, Chen W J, et al. Highexpression of Snail leads to the P-gp modulateds MDR in breast cancer cell MCF-7[J]. Chin Pharmacoll Bull, 2010, 26(1): 87-90.
30. Mire Z, Glenn W K, Simon G. Inhibitors of multidrug resistance (MDR) affinity for MDR substrates[J]. Bioorg Med Chem Lett, 2004, 14: 881-5.
31. Dai C L, Fu L W. The development of the reversal of tumor multidrug resistance[J]. Chin Pharmacol Bull, 2005, 21(5): 513-8.
32. Liu Q, Shuhendler A, Cheng J, et al. Cytotoxicity and mechanism of action of a new ROS-generating microsphere formulation for circumventing multidrug resistance in breast cancer cells[J]. Breast Cancer Res Treat, 2010, 121(2): 323-33.
33. Tan R. The interaction of P-glycoprotein and Chinese medicinal materials or their chemical composition[J]. Chin Hosp Pharm J, 2009, 29(23): 2028-9.